The Pharmacovigilance department has three Units:

1. Public health unit   
2. Clinical practice unit     
3. Clinical trials unit

• Communicate safety information to health practitioners and  the general public through newsletters, the electronic and print media
• Distribute adverse drug reaction (ADR) forms to all health facilities nationwide
• Confirm receipt of Adverse drug reaction( ADR) including Adverse event following immunization (AEFI) reports and give feedback to reporters, participating institutions and other key stakeholders
• Commit  ADR reports to WHO – UMC vigiflow database
• Evaluation of clinical data for registration of new products
• Collaboration with pharmaceutical manufacturers concerning the safety of marketed products
• Conduct hospital inspections 
• Conduct Pharmacovigilance Inspections